#aiingenomics

According to Fortune Business Insights, the global AI in genomics market size was valued at USD 1.36 billion in 2025 and is projected to grow from USD 1.56 billion in 2026 to USD 12.57 billion by 2034, registering a remarkable CAGR of 29.85% during the forecast period. North America dominated the market with a 45.59% share in 2025, driven by advanced healthcare infrastructure and strong AI adoption.

Artificial Intelligence (AI) in genomics involves using machine learning, deep learning, and advanced analytics to interpret DNA/RNA data and generate insights such as:

Disease variant detection

Treatment outcome prediction

Drug target discovery

Precision medicine applications

Key players include QIAGEN, NVIDIA Corporation, Illumina, Inc., and SOPHiA GENETICS, all focusing on advanced AI-driven genomics platforms and software innovation.

MARKET OVERVIEW

AI in genomics is rapidly transforming healthcare and life sciences by enabling:

Faster genomic data interpretation

Scalable analysis of multi-omics datasets

Improved clinical decision-making

The market is strongly driven by:

Explosion of sequencing data

Integration of AI into healthcare workflows

Growth in precision medicine and drug discovery

MARKET TRENDS

Shift Toward Cloud and Hybrid Deployment

A key trend shaping the market is the adoption of cloud and hybrid deployment models.

Key Benefits:

Scalable compute power for large genomic datasets

Faster analysis turnaround times

Reduced infrastructure costs

Improved collaboration across institutions

Hybrid models are gaining traction due to:

Data privacy and regulatory requirements

Need to keep sensitive genomic data on-premise

This trend is also driving:

SaaS-based genomics platforms

Recurring revenue models for vendors

Faster onboarding and system upgrades

MARKET DYNAMICS

MARKET DRIVERS

Rapid Growth in Sequencing and Multi-Omics Data

The surge in genomic data generation is a primary growth driver:

Increased sequencing throughput

Expansion of multi-omics research

Larger cohort-based studies

Impact:

Manual analysis is no longer feasible

Strong demand for AI-driven automation

Increased adoption of scalable analytics platforms

AI enables:

Variant detection and prioritization

Integration of genomic, transcriptomic, and epigenomic data

Faster and more accurate insights

Get Free Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/artificial-intelligence-in-genomics-market-107737

MARKET RESTRAINTS

Data Privacy and Regulatory Constraints

Genomic data is highly sensitive, leading to:

Strict data privacy regulations

Cross-border data transfer limitations

Complex compliance requirements

Impact:

Slower deployment cycles

Increased operational costs

Reduced data-sharing between institutions

MARKET OPPORTUNITIES

Government and Public Health Genomics Initiatives

Government-backed programs are creating strong opportunities:

Population genomics projects

Genomic surveillance systems

Public health data platforms

Benefits:

Stable and long-term funding

Continuous data generation

Increased adoption of AI platforms

These initiatives also support:

Cross-border collaboration

Large-scale longitudinal datasets

Advanced outbreak detection and monitoring

MARKET CHALLENGES

Integration Complexity with Existing Systems

A major challenge is integrating AI solutions with:

LIMS (Laboratory Information Management Systems)

EMR/EHR systems

Existing bioinformatics pipelines

Challenges include:

Custom data mapping

Workflow validation

Regulatory compliance

This leads to:

Longer implementation timelines

Higher dependency on service providers

Adoption barriers despite strong AI capabilities

SEGMENTATION ANALYSIS

By Component

Software

Services

Software dominates due to:

Scalability across multiple sites

Recurring revenue models

Continuous upgrades and innovation

Services are growing rapidly (CAGR 26.83%) due to implementation and integration needs.

By Technology

Machine learning

Natural language processing (NLP)

Machine learning dominates as it powers:

Variant detection

Predictive modeling

Biomarker discovery

NLP is fastest-growing (CAGR 32.79%), enabling:

Clinical report interpretation

Literature mining

Automated insights generation

By Application

Clinical diagnostics

Drug discovery & development

Population genomics

Precision medicine

Clinical diagnostics dominates, driven by:

Rising chronic disease prevalence

Need for rapid diagnosis

Increasing regulatory approvals

Drug discovery is a high-growth segment (CAGR 28.44%).

By Deployment

Cloud-based

On-premise

Hybrid

Cloud-based deployment dominates due to:

High scalability

GPU acceleration for AI models

Easier collaboration

Hybrid deployment is fastest-growing (CAGR 31.08%), balancing flexibility and compliance.

By End User

Pharmaceutical & biotechnology companies

Academic & research institutes

Clinical labs & diagnostic centers

Pharma & biotech companies dominate due to:

Continuous genomics workflows

Large-scale data generation

AI-driven drug discovery

Clinical labs are fastest-growing (CAGR 32.40%).

Get Free Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/artificial-intelligence-in-genomics-market-107737

REGIONAL OUTLOOK

North America

Market size: USD 0.62 billion (2025)

Drivers:

Strong genomics and pharma ecosystem

High AI adoption

Supportive government policies

U.S.

~41.1% global share (2026)

Leading innovation hub

Europe

CAGR: 29.58%

Drivers:

Established genomics research infrastructure

Growing AI investments

Strong regulatory frameworks

Asia Pacific

Rapidly growing region

Market size: USD 0.31 billion (2026)

Drivers:

Increasing sequencing adoption

Expanding biotech sector

Government investments

Key markets:

China

India

Japan

Latin America & Middle East & Africa

Moderate growth

Drivers:

Expanding digital healthcare infrastructure

Increasing AI adoption in healthcare

Key Players

Illumina, Inc.

QIAGEN

SOPHiA GENETICS

NVIDIA Corporation

DNAnexus

Fabric Genomics

Tempus

Velsera

KEY INDUSTRY DEVELOPMENTS

Nov 2025: SOPHiA GENETICS partnered with Complete Genomics for AI-driven oncology solutions

Sept 2025: SeqOne acquired Congenica to expand genomics AI capabilities

July 2025: AWS HealthOmics enhanced workflow deployment capabilities

June 2025: Velsera expanded its global clinico-genomic data network

March 2025: Genomenon launched AI-powered genomic interpretation enhancements

KEY TAKEAWAY

The AI in genomics market is a high-growth, transformative sector (CAGR ~30%), driven by:

Explosion of genomic and multi-omics data

Rising adoption of AI in healthcare

Growth in precision medicine and drug discovery

The human genome contains approximately three billion base pairs of DNA, encoding the biological instructions that govern every cell, organ, and system in the body. For decades, reading and interpreting that information required enormous resources, years of labor, and even then produced only partial understanding. Artificial intelligence is changing that entirely. By combining the raw analytical power of deep learning with the vast datasets generated by modern genomics research, AI is decoding genetic information with a speed, precision, and depth that was previously unthinkable.

The numbers reflect this transformation. The global AI in genomics market was valued at USD 1.15 billion in 2023 and is projected to reach USD 13.64 billion by 2029, growing at a compound annual growth rate of 50.99%. This is among the fastest growth rates of any segment in the life sciences sector, and it signals a shift that reaches far beyond the laboratory.

The Convergence That Is Changing Everything

Understanding why AI and genomics are such a powerful combination requires appreciating what each brings to the relationship. Genomics produces extraordinarily complex data at enormous scale. A single whole-genome sequencing run generates terabytes of information, containing countless variants, mutations, and structural patterns that interact in ways too intricate for conventional analytical methods to fully process.

AI, particularly machine learning and deep learning, thrives precisely in these conditions. Trained on vast genomic and clinical datasets, AI algorithms identify correlations, detect patterns, and generate predictions that would take human researchers years to derive manually. When these capabilities are directed at the genome, the result is a fundamentally new kind of biological insight, one that is faster, more scalable, and increasingly more accurate than anything the field has seen before.

Know More: Global Artificial Intelligence (AI) In Genomics Market - Focused Insights 2024-2029

Genome Sequencing and Annotation: Faster, Smarter, More Precise

One of the most foundational applications of AI in genomics is the acceleration of genome sequencing and annotation. AI-driven algorithms analyze massive genomic datasets and identify patterns and mutations that may be associated with specific diseases, enabling scientists to move from raw sequence data to meaningful clinical insights at unprecedented speed.

This capability is particularly significant for rare and complex diseases, where identifying a causative genetic variant can be like finding a single misprint in a three-billion-character document. AI narrows that search dramatically, flagging variants of interest and predicting their functional consequences with a reliability that manual annotation cannot match at scale.

The downstream effects on clinical practice are profound. When genetic variants can be identified more quickly and interpreted more accurately, patients receive diagnoses faster, treatment plans can be personalized from the outset, and healthcare systems operate more efficiently.

CRISPR Gene Editing: AI as the Architect of Precision

Among the most remarkable intersections of AI and genomics is the application of artificial intelligence to CRISPR-based gene editing. CRISPR technology allows scientists to make targeted modifications to the genome, correcting errors that cause disease or studying gene function with extraordinary specificity. The challenge has always been precision: guiding the CRISPR machinery to exactly the right location in a genome of three billion base pairs, while minimizing edits to unintended locations.

AI is solving this challenge in several ways. Machine learning models are being used to design guide RNAs, the molecular components that direct CRISPR to its target, with much greater efficiency and accuracy than manual design methods allow. These models predict both the cutting efficiency of a given guide RNA and the likelihood of off-target effects, allowing researchers to select the safest and most effective options before any experiment is conducted.

The gene editing segment is growing at the fastest CAGR within the AI in genomics market, reflecting the intense interest from both therapeutic developers and the research community. In vivo gene editing, the ability to modify genes directly within the body without removing and reinserting cells, represents a particularly exciting frontier, and AI is central to making it viable and safe.

Precision Medicine: From Population-Level to Person-Level Care

Perhaps the most transformative long-term application of AI in genomics is in precision medicine. Traditional therapeutic development operates on population averages. A drug is approved because it works for a sufficient proportion of patients in a clinical trial, but individual responses vary enormously based on genetic differences, lifestyle factors, and disease subtype. Precision medicine inverts this model, starting from the individual and working outward.

AI enables this by doing what population-level analysis cannot: integrating genomic, clinical, proteomic, and lifestyle data for individual patients and identifying the specific biological factors driving their condition. In oncology, this means identifying the precise genetic mutations fueling a patient's cancer and matching them to targeted therapies designed for those mutations, rather than applying a generic chemotherapy protocol.

The results are meaningful. Targeted therapies guided by genomic AI analysis deliver higher treatment efficacy and reduce adverse effects, because they work with the biology of the individual patient rather than against it. Beyond cancer, this approach is showing promise in cardiovascular disease, rare genetic disorders, autoimmune conditions, and neurodegenerative diseases.

Machine Learning as the Engine of Drug Discovery

The pharmaceutical and biotechnology sector is among the most active adopters of AI in genomics, and with good reason. Drug discovery has historically been extraordinarily time-consuming and expensive, with the process from target identification to approved therapy often spanning a decade or more and costing billions of dollars. AI is compressing that timeline significantly.

Machine learning algorithms analyze genomic and clinical datasets alongside chemical libraries to identify promising drug candidates faster and with greater efficiency than traditional screening methods. By predicting the efficacy and safety of potential compounds before they enter costly laboratory testing, AI helps pharmaceutical companies focus resources on the candidates most likely to succeed.

This segment, comprising pharma and biotech companies, shows the highest growth rate among all end-user categories in the AI in genomics market. The incentive is straightforward: faster drug development cycles mean faster routes to market, lower development costs, and the ability to address diseases for which no effective treatment currently exists.

The On-Premises and Cloud Infrastructure Underpinning It All

The computational demands of AI-powered genomics are substantial. Genome sequencing produces terabytes of data per run, and the AI models trained to analyze that data require significant processing power and storage infrastructure. On-premises deployment currently holds the largest market share, reflecting the needs of research labs and clinical institutions that require real-time data processing without the latency risks of cloud transmission.

Hospitals and diagnostic centers processing patient imaging and genetic data in time-sensitive clinical contexts depend on on-premises infrastructure for reliability and speed. Research environments generating large-scale sequencing data similarly require local processing capacity. As cloud infrastructure continues to mature and data transmission speeds improve, the balance between on-premises and cloud deployment is expected to shift, but both will remain critical components of the genomics AI ecosystem.

North America Leads in a Global Market

North America holds the largest market share in the global AI in genomics landscape, driven by a combination of advanced healthcare infrastructure, significant public and private investment in genomics research, and a robust ecosystem of technology companies, biotech startups, and academic research institutions. Major vendors including Fabric Genomics, IBM, Microsoft, and NVIDIA are actively shaping the competitive landscape with both established and cutting-edge AI platforms.

The United States and Canada are positioned at the forefront of both AI development and genomics research, creating a natural convergence that accelerates market adoption. Growing awareness among pharmaceutical and biotech companies of the competitive advantages offered by AI-powered genomic tools is further driving adoption across North American markets.

Internationally, the market is characterized by intense competition among global, regional, and local players. The rapid pace of technological development, the scale of investment flowing into drug discovery and healthcare research, and the expanding range of clinical applications are collectively driving innovation across all geographies.

The Phenotypic Data Challenge: A Barrier Worth Watching

The most significant headwind facing the AI in genomics market is the challenge of phenotypic data collection. Phenotypic traits, the observable characteristics of an organism shaped by both genes and environment, are essential context for understanding what genomic variants actually mean in practice. Without high-quality phenotypic data, genomic AI models can identify variants without being able to interpret their clinical significance reliably.

Collecting and standardizing phenotypic data at scale is resource-intensive and methodologically complex. The inherent variability of phenotypic traits across individuals and populations makes standardization difficult, and ensuring consistency across different datasets requires rigorous annotation processes. Ethical and regulatory considerations around data privacy add further complexity. Addressing these challenges will be essential for the field to realize its full potential.

Looking Ahead: A New Era of Biological Discovery

The trajectory of AI in genomics points toward a future of medicine that is more personalized, more predictive, and more effective than anything currently available. As AI models become more sophisticated, as genomic datasets grow larger and more diverse, and as the integration of multi-omics data spanning genomics, proteomics, and metabolomics deepens, the insights generated will become richer and more actionable.

A market growing at nearly 51% annually is sending a clear signal. The convergence of artificial intelligence and genomics is not a future possibility. It is an active, accelerating transformation of biological science and clinical medicine, one that will define healthcare for decades to come. The question is not whether this transformation will happen, but how quickly the innovations emerging from laboratories today will reach the patients who need them most.

AI in Genomics: Revolutionizing Healthcare with a $6.22 Billion Market by 2029

The merger of artificial intelligence and genomics is creating one of the most exciting areas in modern healthcare. A new report from Meticulous Research shows that this fast-growing market is set to reach $6.22 billion by 2029. With a strong annual growth rate of 42.8% from 2022 to 2029, the AI in genomics market is outpacing many other technology sectors and signaling a major change in how we approach medical research and treatment.

What's Fueling This Remarkable Growth?

The rapid growth in AI-powered genomics isn’t happening by chance. Healthcare organizations around the world see that artificial intelligence can unlock the vast potential in our genetic code. The forces behind this growth are both practical and transformative: AI is significantly reducing the time needed for drug discovery, improving the accuracy of diagnostics, and enabling personalized medicine approaches that once seemed like science fiction.

Investment is flowing into this area from both public institutions and private companies, creating a strong ecosystem of innovation. Most importantly, the healthcare industry is becoming more comfortable with AI solutions, breaking down traditional barriers to adoption, which allows genomic AI applications to thrive in research institutions and pharmaceutical companies.

Software Solutions Leading the Charge

When looking at the market, software solutions are leading the way, and for good reason. Unlike one-time purchases, genomic AI software often operates on subscription models or software-as-a-service platforms, providing steady revenue for developers. The pricing for these advanced software solutions reflects their high value, significantly aiding the market’s overall revenue growth.

The quick development of AI algorithms specifically designed for genomic applications is driving ongoing software improvements, making these tools more powerful and appealing to both researchers and clinicians.

Cloud Computing: The New Standard

The delivery of AI genomics solutions is increasingly moving to the cloud. This shift is the fastest-growing segment of the market. Cloud-based platforms offer clear benefits that are hard to overlook: substantial cost savings, greater flexibility in scaling resources, automatic software updates that keep users up to date, and strong data security measures that are often better than what individual organizations can implement.

For pharmaceutical and biotechnology companies managing large genomic datasets, cloud solutions reduce the need for costly on-premises infrastructure while offering the computational power needed for complex AI analyses.

Genome Sequencing: Where AI Makes Its Mark

Among the various applications of AI in genomics, genome sequencing stands out as the largest market segment. This dominance shows AI's particular strength in recognizing patterns and analyzing data. Modern AI systems can detect genetic patterns in vast datasets that would be impossible for human researchers to process by hand. These abilities are invaluable for identifying genes that cause diseases and understanding genetic mutations linked to various health conditions.

Drug Discovery: The Ultimate Prize

The most important application driving market growth is drug discovery and development. Here, AI is changing how pharmaceutical companies handle the traditionally slow and costly process of bringing new medications to market. By analyzing genomic data, AI systems can model how diseases progress, design drug candidates based on individual genetic profiles, and pinpoint promising therapeutic targets with unmatched speed and accuracy.

North America Leading the Way

Geographically, North America currently leads the AI in genomics market, with the United States at the forefront. This leadership comes from significant public and private investments in genomic research and a healthcare system that increasingly embraces AI-driven precision medicine approaches.

However, other regions, especially Europe and Asia-Pacific, are quickly catching up as they recognize the game-changing potential of combining AI with genomic research.

The future of healthcare is written in our genes. Artificial intelligence is providing the tools to read that story with unprecedented clarity and speed.

Key Players

The key players operating in the global AI in genomics market are Microsoft Corporation (U.S.), NVIDIA Corporation (U.S.), Deep Genomics Incorporated (Canada), Fabric Genomics, Inc. (U.S.), Data4Cure, Inc. (U.S.), Predictive Oncology Inc. (U.S.), Emedgene Technologies LTD (U.S.), Congenica Ltd. (U.K.), Tempus Labs, Inc. (U.S.), SOPHiA GENETICS SA (Switzerland), Illumina Inc. (U.S.), and BenevolentAI Limited. (U.K.). Download Sample Copy Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5345